Search

Displaying results 8331 - 8340 of 8389 in total
  1. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Fluocortolone

    go.drugbank.com/drugs/DB08971
    ApprovedWithdrawn

    Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  3. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bio...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  4. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  5. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in co...

  6. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  7. Drug

    Azelnidipine

    go.drugbank.com/drugs/DB09230
    Investigational

    Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increa...

    International brands: Azelnidipine JGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Niguldipine

    go.drugbank.com/drugs/DB09239
    Experimental

    Niguldipine is a calcium channel blocker drug (CCB) with a1-adrenergic antagonist properties.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  9. Drug

    Niludipine

    go.drugbank.com/drugs/DB09240
    Experimental

    Niludipine is a calcium channel blocker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Insulin beef

    go.drugbank.com/drugs/DB09456
    Approved

    Insulin beef has been discontinued in the US and Canada since 2017.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers